• 1.上海交通大學(xué)醫(yī)學(xué)院附屬第三人民醫(yī)院普外科(上海 201900);;
  • 2.上海交通大學(xué)醫(yī)學(xué)院附屬第三人民醫(yī)院病理科(上海 201900);

目的研究胃腺癌組織中CD133蛋白表達(dá)及其臨床意義。方法應(yīng)用免疫組織化學(xué)染色方法檢測(cè)99例胃癌患者手術(shù)切除的原發(fā)灶及正常胃黏膜組織中CD133蛋白的表達(dá)，分析其與臨床病理特征和預(yù)后的關(guān)系。結(jié)果29例(29.29%)患者腫瘤組織中CD133蛋白表達(dá)陽性，正常胃黏膜組織中均為陰性(P=0.000)。 腫瘤直徑 gt;5 cm者CD133蛋白表達(dá)陽性率顯著高于≤5 cm者(P=0.041); CD133蛋白表達(dá)與TNM分期有關(guān)(P=0.044); 有淋巴結(jié)轉(zhuǎn)移(P=0.017)、淋巴管浸潤(P=0.000)和血管浸潤(P=0.000)者，CD133蛋白表達(dá)顯著增高。logistic回歸分析顯示: 腫瘤浸潤深度(P=0.011)、淋巴結(jié)轉(zhuǎn)移(P=0.043)和TNM分期(P＝0.049)分別是CD133蛋白表達(dá)陽性的獨(dú)立危險(xiǎn)因素。CD133蛋白表達(dá)陽性患者的術(shù)后生存時(shí)間短于表達(dá)陰性患者(P＝0.046)。 Cox比例風(fēng)險(xiǎn)回歸模型分析顯示，有淋巴結(jié)轉(zhuǎn)移(P=0.042)、TNM分期(P=0.046)及CD133蛋白表達(dá)陽性(P=0.046)分別是胃癌患者預(yù)后的獨(dú)立危險(xiǎn)因素。結(jié)論胃癌組織中CD133蛋白的表達(dá)與胃癌的發(fā)展、轉(zhuǎn)移及預(yù)后密切相關(guān)。

引用本文： 張鵬,吳巨鋼,俞繼衛(wèi),倪曉春,伍宏彪,李小強(qiáng),姜波健. 胃癌組織中CD133蛋白表達(dá)及其臨床意義. 中國普外基礎(chǔ)與臨床雜志, 2011, 18(3): 281-285. doi: 復(fù)制

1. Crew KD, Neugut AI. Epidemiology of gastric cancer [J]. World J Gastroenterol, 2006, 12(3): 354362.
2. Yu JW, Wu JG, Zheng LH, et al. Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma [J]. J Exp Clin Cancer Res, 2009, 28: 55.
3. Yu JW, Wu JG, Tajima Y, et al. Study on lymph node metastasis is correlated to lymphangiogenesis, lymphatic vessel invasion and lymph node micrometastasis in gastric cancer [J]. J Surg Res, 2009(doi: 10.1016/j.jss.2009.10.03).
4. Yanagita S, Natsugoe S, Uenosono Y, et al. Sentinel node micrometastases have high proliferative potential in gastric cancer [J]. J Surg Res, 2008, 145(2): 238243.
5. Wu Y, Guo E, Yu J, et al. High DcR3 expression predicts stage pN23 in gastric cancer [J]. Am J Clin Oncol, 2008, 31(1): 7983.
6. D’Amour KA, Gage FH. Are somatic stem cells pluripotent or lineagerestricted?[J]. Nat Med, 2002, 8(3): 213214.
7. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells [J]. Nature, 2004, 432(7015): 396401.
8. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44 [J]. Stem Cells, 2009, 27(5): 10061020.
9. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors [J]. Proc Natl Acad Sci USA, 2003, 100(25): 1517815183.
10. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells [J]. Cancer Res, 2005, 65(23): 1094610951.
11. O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice [J]. Nature, 2006, 445(7123): 106110.
12. 張鵬, 俞繼衛(wèi), 姜波健. 腫瘤干細(xì)胞與胃腸道癌發(fā)生和轉(zhuǎn)移 [J]. 中國普外基礎(chǔ)與臨床雜志, 2009, 16(1): 8184.
13. 莫敖, 吳誠義. 腫瘤干細(xì)胞與實(shí)體腫瘤 [J]. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(5): 612614.
14. Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin1 is a potential therapeutic target for antibodydrug conjugates in hepatocellular and gastric cancers [J]. Br J Cancer, 2008, 99(1): 100109.
15. Boegl M, Prinz C. CD133 expression in different stages of gastric adenocarcinoma [J]. Br J Cancer, 2009, 100(8): 13651366.
16. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma-2nd English Edition [J]. Gastric Cancer, 1998, 1(1): 1024.
17. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice [J]. Nature, 1994, 367(6464): 645648.
18. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay [J]. Natl Cancer Inst, 1971, 46(2): 411422.
19. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors [J]. Cancer Res, 2003, 63(18): 58215828.
20. Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells [J]. Biochem Biophys Res Commun, 2006, 351(4): 820824.
21. Miraglia S, Godfrey W, Yin AH, et al. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning [J]. Blood, 1997, 90(12): 50135021.
22. RicciVitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human coloncancerinitiating cells [J]. Nature, 2007, 445(7123): 111115.
23. 張鵬, 吳巨鋼, 姜波健, 等. 胃癌組織中CD133 mRNA表達(dá)及與臨床病理特征的關(guān)系 [J]. 上海交通大學(xué)學(xué)報(bào)醫(yī)學(xué)版, 2010, 30(2): 213217.
24. Mehra N, Penning M, Maas J, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases [J]. Clin Cancer Res, 2006, 12(16): 48594866.
25. Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence [J]. Cancer, 2007, 110(3): 534542.
  1. 1. Crew KD, Neugut AI. Epidemiology of gastric cancer [J]. World J Gastroenterol, 2006, 12(3): 354362.
  2. 2. Yu JW, Wu JG, Zheng LH, et al. Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma [J]. J Exp Clin Cancer Res, 2009, 28: 55.
  3. 3. Yu JW, Wu JG, Tajima Y, et al. Study on lymph node metastasis is correlated to lymphangiogenesis, lymphatic vessel invasion and lymph node micrometastasis in gastric cancer [J]. J Surg Res, 2009(doi: 10.1016/j.jss.2009.10.03).
  4. 4. Yanagita S, Natsugoe S, Uenosono Y, et al. Sentinel node micrometastases have high proliferative potential in gastric cancer [J]. J Surg Res, 2008, 145(2): 238243.
  5. 5. Wu Y, Guo E, Yu J, et al. High DcR3 expression predicts stage pN23 in gastric cancer [J]. Am J Clin Oncol, 2008, 31(1): 7983.
  6. 6. D’Amour KA, Gage FH. Are somatic stem cells pluripotent or lineagerestricted?[J]. Nat Med, 2002, 8(3): 213214.
  7. 7. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells [J]. Nature, 2004, 432(7015): 396401.
  8. 8. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44 [J]. Stem Cells, 2009, 27(5): 10061020.
  9. 9. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors [J]. Proc Natl Acad Sci USA, 2003, 100(25): 1517815183.
  10. 10. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells [J]. Cancer Res, 2005, 65(23): 1094610951.
  11. 11. O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice [J]. Nature, 2006, 445(7123): 106110.
  12. 12. 張鵬, 俞繼衛(wèi), 姜波健. 腫瘤干細(xì)胞與胃腸道癌發(fā)生和轉(zhuǎn)移 [J]. 中國普外基礎(chǔ)與臨床雜志, 2009, 16(1): 8184.
  13. 13. 莫敖, 吳誠義. 腫瘤干細(xì)胞與實(shí)體腫瘤 [J]. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(5): 612614.
  14. 14. Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin1 is a potential therapeutic target for antibodydrug conjugates in hepatocellular and gastric cancers [J]. Br J Cancer, 2008, 99(1): 100109.
  15. 15. Boegl M, Prinz C. CD133 expression in different stages of gastric adenocarcinoma [J]. Br J Cancer, 2009, 100(8): 13651366.
  16. 16. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma-2nd English Edition [J]. Gastric Cancer, 1998, 1(1): 1024.
  17. 17. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice [J]. Nature, 1994, 367(6464): 645648.
  18. 18. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay [J]. Natl Cancer Inst, 1971, 46(2): 411422.
  19. 19. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors [J]. Cancer Res, 2003, 63(18): 58215828.
  20. 20. Suetsugu A, Nagaki M, Aoki H, et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells [J]. Biochem Biophys Res Commun, 2006, 351(4): 820824.
  21. 21. Miraglia S, Godfrey W, Yin AH, et al. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning [J]. Blood, 1997, 90(12): 50135021.
  22. 22. RicciVitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human coloncancerinitiating cells [J]. Nature, 2007, 445(7123): 111115.
  23. 23. 張鵬, 吳巨鋼, 姜波健, 等. 胃癌組織中CD133 mRNA表達(dá)及與臨床病理特征的關(guān)系 [J]. 上海交通大學(xué)學(xué)報(bào)醫(yī)學(xué)版, 2010, 30(2): 213217.
  24. 24. Mehra N, Penning M, Maas J, et al. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases [J]. Clin Cancer Res, 2006, 12(16): 48594866.
  25. 25. Lin EH, Hassan M, Li Y, et al. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence [J]. Cancer, 2007, 110(3): 534542.